


Data Sheet

Product Name:	ARS-1630
Cat. No.:	CS-0035117
CAS No.:	1698055-86-5
Molecular Formula:	C ₂₁ H ₁₇ ClF ₂ N ₄ O ₂
Molecular Weight:	430.84
Target:	Ras
Pathway:	GPCR/G Protein
Solubility:	DMSO : ≥ 69 mg/mL (160.15 mM)



BIOLOGICAL ACTIVITY:

ARS-1630, a less active enantiomer of ARS-1620, is a novel inhibitor of **mutant K-ras G12C** extracted from patent WO 2015054572 A1. IC₅₀ & Target: K-Ras G12C^[1] **In Vitro:** KRAS^{G12C} is recently identified to be potentially druggable by allele-specific covalent targeting of Cys-12 in vicinity to an inducible allosteric switch II pocket (S-IIP). Success of this approach requires active cycling of KRAS^{G12C} between its active-GTP and inactive-GDP conformations as accessibility of the S-IIP is restricted only to the GDP-bound state. This strategy proves feasible for inhibiting mutant KRAS in vitro^[2].

PROTOCOL (Extracted from published papers and Only for reference)

Animal Administration: ARS-1620 is formulated in water solution with 1% N-methyl-2-pyrrolidone, 19% polyethylene glycol 400, and 10% cyclodextrin and then sterilized by filtration for IV dosing.

References:

[1]. Liansheng Li, et al. Inhibitors of kras g12c. WO 2015054572 A1.

[2]. Janes MR, et al. Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor. Cell. 2018 Jan 25;172(3):578-589.e17.

CAIndexNames:

2-Propen-1-one, 1-[4-[(7R)-6-chloro-8-fluoro-7-(2-fluoro-6-hydroxyphenyl)-4-quinazolinyl]-1-piperazinyl]-

SMILES:

C=CC(N1CCN(C2=C3C=C(Cl)[C@@]([C@@]4=C(O)C=CC=C4F)=C(F)C3=NC=N2)CC1)=O.[R]

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 732-484-9848 Fax: 888-484-5008 E-mail: sales@ChemScene.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA